Destiny Pharma: Interim results for the six months ended 30 June 2022

iOmx Therapeutics appoints Professor Frances Balkwill to the Scientific Advisory Board

Destiny Pharma announces positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans

ABIVAX PHASE 2B STUDY RESULTS OF OBEFAZIMOD (ABX464) IN ULCERATIVE COLITIS PUBLISHED IN THE LANCET GASTROENTEROLOGY & HEPATOLOGY

Spexis provides business update and announces financial results for the first half of 2022

ABIVAX PUBLISHES A PROSPECTUS IN THE CONTEXT OF ITS CAPITAL INCREASE

ABIVAX ANNOUNCES SUCCESSFUL OVERSUBSCRIBED EUR 49.2M CROSS-OVER FINANCING WITH TOP-TIER US AND EUROPEAN BIOTECH INVESTORS

AiCuris appoints experienced business leader Dr. Sabrina Kuttruff-Coqui as Chief Financial Officer

Carbios strengthens Executive Committee with the appointment of Pascal Bricout as Chief Strategy & Financial Officer

Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication